Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PROPHYLACTIC AND THERAPEUTIC AGENT FOR COMPLICATIONS AFTER CATARACT SURGERY
Document Type and Number:
WIPO Patent Application WO/2016/175228
Kind Code:
A1
Abstract:
Provided is a novel drug for preventing and treating complications after cataract surgery such as secondary cataract and anterior capsular contraction occurring after cataract surgery. The prophylactic and therapeutic agent according to the present invention for complications after cataract surgery such as secondary cataract and anterior capsular contraction comprises, as an active ingredient, 4-fluoro-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline (ripasudil), a salt thereof or a solvate of the same.

Inventors:
HONJO MEGUMI (JP)
OHTA MASAYUKI (JP)
Application Number:
PCT/JP2016/063149
Publication Date:
November 03, 2016
Filing Date:
April 27, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HONJO MEGUMI (JP)
KOWA CO (JP)
International Classes:
A61P27/02; A61K31/551; A61P43/00
Foreign References:
JP2013513664A2013-04-22
JP2013035802A2013-02-21
Other References:
CHO ET AL.: "Rho activation is required for transforming growth factor-beta-induced epithelial-mesenchymal transition in lens epithelial cells", CELL BIOLOGY INTERNATIONAL, vol. 31, no. 10, 25 April 2007 (2007-04-25), pages 1225 - 1230, XP022145676
YAMAMOTO ET AL.: "The novel Rho Kinase (ROCK) Inhibitor K-115: A New Candidate Drug for Neuroprotective Treatment in Glaucoma", INVESTIGATIVE OPHTHAMOLOGY & VISUAL SCIENCE, vol. 55, no. 11, November 2014 (2014-11-01), pages 7126 - 7136, XP055326441
MADDALA ET AL.: "Growth factor induced activation of Rho and Rac GTPases and actin cytoskeletal reorganization in human lens epithelial cells", MOLECULAR VISION, vol. 9, 17 July 2003 (2003-07-17), pages 329 - 336, XP055326445
See also references of EP 3290040A4
Attorney, Agent or Firm:
SAEKI, Norio et al. (JP)
Norio Saeki (JP)
Download PDF: